Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Precision BioSciences Inc

Healthcare US DTIL

6.95USD
-0.13(1.84%)

Last update at 2026-06-23T20:00:00Z

Day Range

6.777.29
LowHigh

52 Week Range

3.538.82
LowHigh

Fundamentals

  • Previous Close 7.08
  • Market Cap191.98M
  • Volume294117
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-50.68000M
  • Revenue TTM34.26M
  • Revenue Per Share TTM2.67
  • Gross Profit TTM 34.26M
  • Diluted EPS TTM-3.63

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -46.60900M 7.17M -42.52700M -111.63700M -30.60200M
Minority interest - - - - -
Net income -46.60900M 7.17M -61.31900M -122.90800M -30.91800M
Selling general administrative 32.24M 35.30M 39.09M 41.52M 39.69M
Selling and marketing expenses - - 4.23M - -
Gross profit 31.51M 68.70M 48.73M 25.10M 115.53M
Reconciled depreciation 2.75M 4.58M 8.97M 9.00M 10.20M
Ebit -52.14800M 8.95M -40.29700M -100.36600M -39.40200M
Ebitda -49.39500M 13.53M -32.04200M -98.47200M -28.81300M
Depreciation and amortization 2.75M 4.58M 8.26M 1.89M 10.59M
Non operating income net other - - - -11.27100M 8.80M
Operating income -52.14800M -26.16200M -43.73600M -100.36600M -39.40200M
Other operating expenses 86.41M 94.86M 92.46M 125.46M 154.93M
Interest expense 1.42M 1.78M 2.23M 1.11M 0.13M
Tax provision - - - - -
Interest income 4.24M 6.76M 7.80M 3.47M 0.21M
Net interest income 2.82M 4.98M 5.66M 2.36M 0.08M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 27.24M 11.27M 0.32M
Total revenue 34.26M 68.70M 48.73M 25.10M 115.53M
Total operating expenses 83.66M 94.86M 92.46M 125.46M 154.93M
Cost of revenue 2.75M 4.58M 8.26M - -
Total other income expense net 5.54M 33.33M 1.21M -11.27100M 8.80M
Discontinued operations - - - - -
Net income from continuing ops -46.60900M 7.17M -87.24800M -111.63700M -30.60200M
Net income applicable to common shares - - - -111.63700M -30.60200M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 154.42M 136.39M 159.78M 238.17M 211.50M
Intangible assets 1.17M 0.62M 0.40M 1.35M 2.05M
Earning assets - - - - -
Other current assets 3.15M 6.98M 6.88M 1.26M 0.17M
Total liab 62.17M 80.00M 140.92M 177.74M 120.33M
Total stockholder equity 92.25M 56.39M 18.86M 60.43M 91.17M
Deferred long term liab - - - - -
Other current liab 7.11M 9.39M 11.44M 10.21M 11.77M
Common stock 0.00100M 0.00100M 0.00100M 0.00100M -
Capital stock 0.00100M 0.00100M 0.00100M 0.00100M 0.00000M
Retained earnings -528.18800M -482.46400M -489.63100M -428.31200M -316.67500M
Other liab - - - 93.07M 77.06M
Good will - - - - -
Other assets - - 0.00000M 9.80M 11.52M
Cash 110.82M 85.90M 116.68M 189.58M 143.66M
Cash and equivalents - - - - -
Total current liabilities 8.91M 14.98M 49.99M 59.66M 35.98M
Current deferred revenue - 2.96M 12.04M 46.19M 21.24M
Net debt -82.01500M -55.85400M -85.41000M -162.54000M -134.55000M
Short term debt 1.51M 1.32M 23.55M 2.04M 1.82M
Short long term debt - - 22.41M - -
Short long term debt total 28.81M 30.05M 31.27M 27.04M 9.11M
Other stockholder equity 620.43M 538.86M 508.49M 488.74M 407.84M
Property plant equipment - - - 20.19M 25.15M
Total current assets 118.74M 94.99M 136.36M 199.10M 161.75M
Long term investments 0.74M 3.21M 3.21M 9.41M 10.63M
Net tangible assets - - - 59.09M 89.12M
Short term investments 4.76M 0.41M - - -
Net receivables 0.00000M 1.70M 12.80M 0.72M 0.49M
Long term debt 22.40M 22.32M - 22.22M 2.48M
Inventory - - - 7.55M 17.43M
Accounts payable 0.30M 1.31M 2.97M 1.23M 1.14M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - -428.31200M -316.67500M
Treasury stock - - - -0.95200M -0.95200M
Accumulated amortization - - - - -
Non currrent assets other 26.54M 27.39M 0.23M 9.80M 4.64M
Deferred long term asset charges - - - - -
Non current assets total 35.68M 41.40M 23.42M 39.06M 49.74M
Capital lease obligations 6.40M 7.72M 8.86M 4.81M 6.63M
Long term debt total - - - 22.22M 2.48M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.21500M 5.16M -3.31900M -5.80300M
Change to liabilities - - - 0.15M 0.87M
Total cashflows from investing activities -0.63400M -0.21500M 5.83M -3.31900M -5.80300M
Net borrowings 0.00000M -0.03700M 0.00000M 19.80M -0.04800M
Total cash from financing activities 95.16M 50.45M 5.39M 94.98M 70.52M
Change to operating activities - - - -3.16900M 2.37M
Net income -45.72400M 7.17M -61.31900M -111.63700M -30.60200M
Change in cash 28.68M -8.21000M -72.89800M 45.91M 53.87M
Begin period cash flow 108.47M 116.68M 189.58M 143.66M 89.80M
End period cash flow 137.15M 108.47M 116.68M 189.58M 143.66M
Total cash from operating activities -65.84300M -58.44500M -84.11400M -45.75300M -10.85300M
Issuance of capital stock 94.94M 50.24M 2.16M 74.34M 60.48M
Depreciation 2.75M 4.58M 8.26M 9.00M 10.20M
Other cashflows from investing activities -0.54900M -0.02500M 0.11M - -0.75000M
Dividends paid - - - - -
Change to inventory - - - - 4.30M
Change to account receivables 0.23M 10.42M -0.18100M -0.23200M 9.51M
Sale purchase of stock - - - 74.74M 67.26M
Other cashflows from financing activities 95.16M 0.25M 0.40M 20.64M 12.54M
Change to netincome - - - 32.83M -10.07800M
Capital expenditures 0.09M 0.25M 2.28M 3.32M 5.80M
Change receivables - - - -0.23200M 9.51M
Cash flows other operating - - - 25.04M 10.41M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 45.91M 53.87M
Change in working capital -24.70800M -53.99900M -41.48700M 24.11M 19.58M
Stock based compensation 10.19M 12.60M 14.04M 19.20M 16.51M
Other non cash items -8.35000M -28.79400M -3.60300M 13.57M -20.40300M
Free cash flow -65.92800M -58.69500M -86.39200M -49.07200M -16.65600M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DTIL
Precision BioSciences Inc		 -0.13 1.84% 6.95 - 14.08 5.60 2.12 3.18 -0.2741
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Precision BioSciences Inc

302 East Pettigrew St., Durham, NC, United States, 27701

Key Executives

Name Title Year Born
Mr. Michael Amoroso Pres, CEO & Director 1978
Dr. Derek Jantz Ph.D. Co-Founder, Chief Scientific Officer & Strategy 1976
Mr. John Alexander Kelly Chief Financial Officer 1967
Dr. Jefferson J. Smith Ph.D. Co-Founder & Chief Research Officer NA
Mr. Shane Barton VP, Corp. Controller & Principal Accounting Officer 1971
Mei Burris Director of Investor Relations & Fin. NA
Mr. Dario Scimeca Gen. Counsel & Sec. 1975
Mr. Bruce Stevens VP of Quality & Compliance NA
Ms. Heather King Director of Marketing Communications & PR NA
Maurissa Messier Sr. Director of Corp. Communications NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions